XTL Biopharmaceuticals Ltd.

XTLB
$2.85 (- $0.03 - 1.04%)
Last updated: 2026-08-06 06:16 UTC
XTLB Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS98386D4060
CUSIP98386D406
Market Price2.85
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-0.3
Market Cap$6.7M
Book Value0.01
Price to Book123.15
Beta0.92
52w High2.57
52w Low0.7
Next Earnings DateN/A

XTL Biopharmaceuticals Ltd. trades under ticker XTLB on NASDAQ as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US98386D4060, CUSIP 98386D406. Also searched as XTL Biopharmaceuticals.

Related researchXTLB stock priceXTLB share priceXTL Biopharmaceuticals stockXTL Biopharmaceuticals share price98386D406
About the Company
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Price History